List of Excipients in Branded Drug KETOCONAZOLE

Generic Drugs Containing KETOCONAZOLE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	ketoconazole	0093-3219	CETYL ALCOHOL
Teva Pharmaceuticals USA Inc	ketoconazole	0093-3219	ISOPROPYL MYRISTATE
Teva Pharmaceuticals USA Inc	ketoconazole	0093-3219	POLYSORBATE 60
Teva Pharmaceuticals USA Inc	ketoconazole	0093-3219	POLYSORBATE 80
Teva Pharmaceuticals USA Inc	ketoconazole	0093-3219	PROPYLENE GLYCOL
Teva Pharmaceuticals USA Inc	ketoconazole	0093-3219	SODIUM SULFITE

What are the Most Frequently-Used Excipients in KETOCONAZOLE?

# Of NDCs	Excipient
8	ALCOHOL
1	AQUA
7	BRUCINE SULFATE
7	BUTANE
16	BUTYLATED HYDROXYANISOLE
24	CELLULOSE, MICROCRYSTALLINE

Ketoconazole Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Ketoconazole is a mature, low-cost imidazole antifungal with limited active-ingredient patent protection and substantial formulation latitude. The strongest commercial opportunities are topical products that improve solubility, skin deposition, tolerability, cosmetic acceptability, and channel access. Oral ketoconazole has limited development value because of hepatotoxicity, adrenal suppression, drug interactions, and FDA restrictions on systemic use.[1]

What formulation problems must ketoconazole excipients solve?

Ketoconazole is practically insoluble in water and behaves as a weakly basic compound with pH-dependent solubility. Its formulation risks differ by dosage form:

Dosage form	Primary technical challenge	Commercial implication
Oral tablet	Low and variable dissolution; gastric-acidity dependence	Limited opportunity because safety risks constrain systemic use
Cream	Low aqueous solubility; need for epidermal and follicular delivery	Strongest opportunity for differentiated topical products
Shampoo	Uniform dispersion, rinse-off deposition, foam, scalp tolerability	Attractive for dandruff and seborrheic dermatitis markets
Foam	Solubilization, propellant compatibility, evaporation, residue	Premium product opportunity if vehicle improves adherence
Gel or lotion	Solubility, spreadability, drying time, irritation	Potential for specialty dermatology and private-label products
Nail or follicular delivery	Barrier penetration and sustained residence time	Higher technical risk but greater differentiation potential

Ketoconazole must be formulated to maintain adequate drug activity without creating excessive irritation. Solvent concentration, surfactant selection, pH, preservative system, and particle size directly affect performance.

Which excipients are used in approved ketoconazole products?

Oral tablets

Generic ketoconazole tablets commonly use a conventional wet- or dry-granulation excipient system that includes:

• Lactose monohydrate
• Corn starch
• Microcrystalline cellulose
• Povidone
• Sodium starch glycolate
• Colloidal silicon dioxide
• Magnesium stearate

These excipients support powder flow, granulation, tablet strength, disintegration, and lubrication. The system is technically straightforward, but oral ketoconazole is commercially constrained by its safety profile rather than by tablet technology.[2]

Food, gastric pH, antacids, proton-pump inhibitors, and H2 antagonists can affect absorption. The FDA states that oral ketoconazole should not be used as first-line therapy for fungal infections and should be reserved for serious infections when alternatives are unavailable or not tolerated.[1]

2% cream

Common ketoconazole cream vehicles use a water-in-oil or oil-in-water emulsion containing:

• Propylene glycol
• Cetyl alcohol
• Stearyl alcohol
• Sorbitan monostearate
• Polysorbate 60
• Isopropyl myristate
• Sodium sulfite
• Purified water

This excipient architecture provides emolliency, emulsification, spreading, and drug solubilization. Propylene glycol is particularly important because it can act as a cosolvent and penetration enhancer. Its concentration must be balanced against stinging and irritant dermatitis.

Cetyl and stearyl alcohols increase viscosity and improve skin feel. Sorbitan monostearate and polysorbate 60 stabilize the emulsion. Isopropyl myristate improves spreadability and may increase dermal partitioning, but it can create variability in skin deposition and may be undesirable for acne-prone or sensitive patients.[3]

2% shampoo

Ketoconazole shampoos generally contain an anionic or amphoteric cleansing system, viscosity modifiers, conditioning agents, preservatives, fragrance, and pH adjusters. Representative excipient classes include:

• Sodium laureth sulfate
• Disodium laureth sulfosuccinate
• Coconut-derived diethanolamide or related foam boosters
• PEG-based viscosity modifiers
• Sodium chloride
• Citric acid or hydrochloric acid
• Preservatives
• Fragrance
• Purified water

The formulation must keep ketoconazole uniformly dispersed during storage and provide sufficient scalp contact before rinsing. Excessive detergency can undermine adherence by increasing dryness, itching, or irritation. A milder surfactant system is a practical differentiation route for pediatric, sensitive-scalp, and frequent-use products.[4]

Foam products

Ketoconazole foam products use fatty alcohols, water, alcohol, surfactants, preservatives, and a propellant system. Foam delivery can improve application to hair-bearing areas by reducing dripping and shortening drying time.

The main formulation risks are:

• Drug precipitation during manufacture or storage
• Propellant and valve compatibility
• Foam collapse
• Flammability
• Residual tackiness
• Cold or burning sensation after application

A foam may command a higher price than a cream or shampoo if it reduces application friction and improves patient adherence. The value proposition is strongest for scalp, beard, chest, and other hair-bearing sites.

What excipient strategies offer the best commercial opportunities?

Can solubilization create a differentiated ketoconazole product?

Yes. Solubilization is the most direct technical strategy for improving product uniformity and dermal availability.

Candidate approaches include:

• Propylene glycol and ethanol cosolvent systems
• Polyethylene glycol-based vehicles
• Transcutol-type glycols
• Poloxamers
• Cyclodextrin complexes
• Lipid-based microemulsions
• Self-emulsifying systems
• Nanoemulsions

A successful system must avoid crystallization after application. Supersaturated formulations can increase thermodynamic activity, but precipitation control becomes central to shelf life and in-use performance.

Are lipid and nanocarrier systems commercially attractive?

They are technically attractive but commercially selective. Liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, and transfersomes can improve deposition in the stratum corneum or follicular units.

Potential advantages include:

• Greater local drug loading
• Reduced systemic exposure
• Sustained release
• Lower solvent exposure
• Improved skin hydration
• Better follicular targeting

The commercial barrier is manufacturing complexity. Nanocarrier products require tighter controls for particle size, polydispersity, morphology, encapsulation efficiency, microbial quality, and release testing. A simple emulsion or hydroalcoholic gel will usually have a lower cost of goods and an easier generic or 505(b)(2) development path.

Can low-irritancy excipients support premium positioning?

Yes. A product can be differentiated through removal or reduction of:

• Fragrance
• High alcohol levels
• Sodium lauryl sulfate-type surfactants
• Formaldehyde-releasing preservatives
• High propylene glycol concentrations
• Certain parabens, depending on market positioning
• Excessive essential oils

A preservative-free single-dose or airless-pump product may be attractive for sensitive skin, but packaging cost and microbiological validation become material. “Sensitive scalp,” “fragrance-free,” and “dermatologist-tested” positioning can support premium pricing only if the vehicle produces measurable improvements in tolerability or adherence.

What formulations are protected or differentiated by intellectual property?

The ketoconazole active ingredient is no longer the main source of exclusivity. Commercial protection is more likely to arise from:

1. Specific solvent ratios.
2. Surfactant combinations.
3. Particle-size distributions.
4. Liposomal or nanoparticle compositions.
5. Foam and aerosol systems.
6. Preservative-free packaging.
7. Controlled-release gels or films.
8. Combination products with corticosteroids, keratolytics, or antibacterial agents.
9. Methods targeting seborrheic dermatitis, pityriasis versicolor, dermatophytosis, or folliculitis.
10. Manufacturing processes that prevent crystallization or improve batch uniformity.

A formulation patent must provide more than a familiar list of excipients. The strongest claims generally require defined concentration ranges, performance characteristics, or unexpected results such as improved skin deposition, lower irritation, better stability, or reduced wash-off.

When did ketoconazole lose active-ingredient exclusivity?

Ketoconazole’s core small-molecule patent protection expired decades ago. The historical U.S. compound patent is commonly identified as U.S. Patent No. 4,144,346, assigned to Janssen Pharmaceutica. Its effective protection ended before the modern generic market matured.

Milestone	Approximate timing	Commercial effect
U.S. ketoconazole compound patent issued	1979	Original compound protection
Oral Nizoral approval	1981	Initial systemic market
Topical products introduced	1980s-1990s	Expansion into dermatology
Core compound exclusivity ended	1990s	Generic entry became possible
FDA systemic-use safety restrictions	2013	Oral market narrowed materially
Current market	Generic and branded topical products	Formulation, channel, and brand differentiation dominate

The exact scope of later formulation or method-of-use patents must be checked in the relevant jurisdiction. The expired compound patent does not eliminate possible protection for later delivery systems or combinations.

What is the Orange Book status of ketoconazole?

Ketoconazole is an approved small-molecule drug, not a biologic. Approved products may appear under different application holders and dosage forms in FDA databases. The Orange Book analysis should distinguish:

• Oral tablets
• Topical creams
• Topical shampoos
• Foams and other semisolid products

The key commercial point is that ketoconazole does not have a meaningful current compound-patent barrier comparable to a recently approved branded drug. Generic applicants generally compete through ANDAs, subject to dosage-form-specific requirements and product-specific bioequivalence or pharmaceutical-equivalence standards.[5]

For topical products, the regulatory pathway may be more complex than a conventional tablet ANDA because local delivery, formulation composition, dermatopharmacokinetics, and comparative clinical performance can affect approval strategy. A product that is qualitatively or quantitatively different from the reference product may require a 505(b)(2) approach rather than a standard ANDA.

Which companies are challenging ketoconazole exclusivity?

Ketoconazole has already experienced broad generic competition. The relevant competitive set includes:

• Generic tablet manufacturers
• Contract manufacturers supplying topical creams and shampoos
• Branded and store-brand dandruff products
• Dermatology companies selling prescription-strength topical products
• Veterinary manufacturers
• OTC consumer-health companies

Current competition is commercial rather than patent-driven. The main barriers are manufacturing scale, product quality, pharmacy contracting, retail distribution, brand recognition, and regulatory substitution.

A new entrant is unlikely to win solely by offering the same 2% cream at a lower price. It needs a cost or performance advantage, such as:

• Lower manufacturing cost
• Better texture and absorption
• Faster drying
• Reduced residue
• Improved scalp tolerability
• Convenient packaging
• Lower minimum order quantities for private-label customers
• Stronger stability in hot and humid markets

Are Paragraph IV challenges relevant to ketoconazole?

Paragraph IV litigation is generally less important for the mature ketoconazole market than for products with unexpired Orange Book-listed patents. A Paragraph IV certification is relevant only when an ANDA applicant seeks approval for a product referencing an NDA with listed patents that remain legally enforceable.

For ketoconazole, the larger risks are:

• Formulation patent claims covering a differentiated product
• Method-of-use patents for a specific indication
• Patent disputes over combination therapy
• Trade-secret claims involving manufacturing
• Trademark and trade-dress disputes
• Regulatory exclusivity attached to a newer reference product

An applicant relying on an old reference product should still conduct a current Orange Book and patent-family review before launch. The commercial baseline, however, is generic competition without a material active-ingredient patent constraint.

Does ketoconazole face biosimilar risk?

No. Ketoconazole is a synthetic small molecule. Biosimilar regulation does not apply. The competitive threats are generic substitution, branded-generic products, OTC antifungal products, veterinary products, and alternative antifungals such as clotrimazole, miconazole, terbinafine, ciclopirox, and selenium sulfide.

How does ketoconazole compare with competing antifungals?

Product	Main strength	Formulation opportunity	Competitive weakness
Ketoconazole	Broad topical antifungal use; established clinical familiarity	Cream, shampoo, foam, gel, nano- and lipid systems	Mature product and limited systemic use
Terbinafine	Strong activity against dermatophytes	Cream, spray, gel, film-forming systems	Less natural fit for some yeast-associated scalp conditions
Clotrimazole	Broad OTC availability	Cream, solution, combination products	Heavy price competition
Miconazole	OTC and prescription presence	Cream, powder, spray, vaginal products	Crowded retail market
Ciclopirox	Multiple topical dosage forms	Nail lacquer, cream, shampoo	Smaller commercial base
Selenium sulfide	Established dandruff use	Shampoo and lotion	Cosmetic acceptability and staining concerns

Ketoconazole has the clearest formulation opportunity in scalp and seborrheic dermatitis products. Terbinafine is often stronger in dermatophyte-focused markets, while clotrimazole and miconazole exert greater OTC price pressure.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate for creams and shampoos and higher for foams and nanocarriers.

Lower-barrier products

• Conventional cream
• Lotion
• Shampoo
• Hydroalcoholic gel
• Simple solution or suspension

Higher-barrier products

• Foam aerosol
• Liposomal ketoconazole
• Nanostructured lipid carrier
• Controlled-release film
• Microneedle or follicular delivery system
• Preservative-free multidose product

Critical manufacturing controls include particle-size distribution, mixing order, temperature history, pH, viscosity, microbial limits, preservative effectiveness, and prevention of ketoconazole crystallization.

A formulation patent is stronger when it connects composition to a defined technical result. Broad claims covering “ketoconazole plus a solvent” are more vulnerable to invalidity or design-around than claims requiring a narrow ratio, a specific microstructure, or demonstrated performance.

What licensing deals and partnership models are available?

Ketoconazole’s mature active ingredient makes large asset-level licensing less likely. Commercial opportunities are more compatible with:

• Contract development and manufacturing agreements
• Private-label supply
• Regional distribution licenses
• Retail or pharmacy-channel partnerships
• Dermatology co-promotion
• Veterinary formulation licenses
• Platform licenses for lipid, foam, or nano-delivery systems

A licensee is most likely to pay for a differentiated delivery platform, regulatory package, manufacturing process, or established distribution network rather than for ketoconazole itself.

What generic launch scenarios are commercially realistic?

Low-cost conventional generic

A standard cream or shampoo can launch quickly if the applicant matches the reference product’s quality, stability, and regulatory requirements. Margin pressure will be high.

Premium topical reformulation

A fragrance-free, low-irritancy cream or shampoo can support higher pricing if clinical or consumer data demonstrate better tolerability or adherence. The product may require a 505(b)(2) strategy if it departs materially from the reference formulation.

Specialty foam

A foam can target hair-bearing sites and patients dissatisfied with creams or shampoos. Its principal risks are development cost, aerosol manufacturing, flammability controls, and market education.

Private-label platform

A manufacturer can offer multiple ketoconazole products with the same active ingredient but different vehicles, packaging, and claims. This model is attractive for pharmacy, dermatology, veterinary, and international markets.

Veterinary expansion

Veterinary shampoos and topical combinations can provide incremental demand, but species-specific safety, regulatory requirements, and channel economics must be addressed separately from human products.

What is the revenue exposure and market outlook?

Ketoconazole revenue is fragmented across generic prescription products, OTC or quasi-OTC shampoo products, dermatology brands, and veterinary formulations. Product-level revenue disclosure is limited because manufacturers often report ketoconazole within broader dermatology or consumer-health portfolios.

The most defensible commercial thesis is:

• Oral ketoconazole has low strategic attractiveness.
• Conventional topical products have high volume but low margins.
• Premium shampoos and foams offer better pricing potential.
• Novel delivery systems offer the strongest IP opportunity but carry the highest development risk.
• Private-label and regional distribution can produce faster commercialization than a new branded prescription launch.

Key Takeaways

• Ketoconazole’s core active-ingredient exclusivity expired decades ago.
• The commercial value is concentrated in topical products, not oral therapy.
• Propylene glycol, surfactants, fatty alcohols, emulsifiers, and preservative systems define current formulation architecture.
• The best excipient opportunities involve solubilization, lower irritation, improved scalp deposition, faster drying, and better cosmetic performance.
• Foam, lipid, nano, and controlled-release products can create formulation IP, but they require stronger manufacturing controls.
• Biosimilar risk does not apply.
• Paragraph IV litigation is less important than formulation patents, method-of-use claims, regulatory pathway selection, and commercial execution.
• Generic creams and shampoos face severe price competition.
• Premium scalp products, private-label platforms, veterinary products, and differentiated delivery systems offer the clearest commercial opportunities.

FAQs

Is ketoconazole soluble in water?

No. Ketoconazole has very low aqueous solubility. Formulators typically use cosolvents, surfactants, emulsions, lipid systems, or particle engineering to maintain uniformity and drug availability.

Which ketoconazole dosage form has the highest commercial potential?

Topical shampoo and foam products have the strongest premium potential because they can improve scalp application, cosmetic acceptability, and adherence. Conventional cream has greater volume potential but lower margins.

Can ketoconazole be developed as an OTC product?

Some ketoconazole topical products may be marketed through nonprescription channels depending on strength, indication, jurisdiction, and regulatory classification. U.S. regulatory status must be evaluated by product and labeling rather than inferred from the active ingredient alone.[4]

What is the most defensible ketoconazole formulation patent strategy?

The strongest strategy generally combines a defined excipient range with measurable performance, such as improved stability, reduced crystallization, enhanced skin deposition, lower irritation, or controlled release.

Is oral ketoconazole still commercially attractive?

Usually not. FDA safety restrictions, hepatotoxicity, adrenal effects, drug interactions, and the availability of safer antifungals substantially limit the commercial case for new oral ketoconazole products.[1]

References

1. U.S. Food and Drug Administration. (2013). FDA drug safety communication: FDA limits usage of Nizoral oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. https://www.fda.gov
2. DailyMed. (n.d.). Ketoconazole tablet, film coated: Prescribing information and inactive ingredients. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov
3. DailyMed. (n.d.). Ketoconazole cream, 2%: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov
4. U.S. Food and Drug Administration. (n.d.). Nizoral ketoconazole shampoo and topical product labeling. https://www.accessdata.fda.gov
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book